Marisa Wexler, MS,  senior science writer—

A novel gene-editing treatment platform corrected the mutation that causes cystic fibrosis (CF) in multiple tissues throughout the bodies of mice, according to results of a first-of-its-kind study. “This is the first study looking at treating multiple organs affected by CF with a single gene editing treatment administered intravenously,” Alexandra…

Anemia is common among lung transplant recipients, and people with cystic fibrosis (CF) are at more than four times greater risk of developing anemia post-transplant compared to those with other lung diseases. That’s according to the study “Post-Transplantation Anemia and Risk of Death Following Lung Transplantation,”…

Vitamin C supplements can increase how long vitamin E stays active in the body in people with cystic fibrosis (CF), a small study suggests. “It would seem to be clinically prudent for CF clinicians and nutritionists to recognize the importance of dietary and supplemental vitamin C levels and their…

The average lifespan for someone with cystic fibrosis (CF) is markedly longer in France than in Canada or Australia, a new study reports. Programs that help facilitate access to lung transplants in France may in part explain the difference, according to researchers. “For multiple reasons, which will need to…

A measure of lung function called the lung clearance index can detect impaired lung function in children with cystic fibrosis (CF) at earlier ages than standard spirometry, a new study suggests. The study, “Pulmonary exacerbations, airway pathogens, and long-term course of lung clearance index in children…

Getting vaccinated against Coxsackie B viruses (CVB) may help prevent people with cystic fibrosis (CF) from getting ill, according to a new study of CF mouse models. “This study shows that CVB infections are common in the CF population and we provide preclinical evidence that CVB infections are preventable…

Voting is now open for the 2022 Thriving Undergraduate and Thriving Graduate Scholarships — a grant program for students with cystic fibrosis (CF) that is run by AbbVie. This year marks the 30th anniversary of the scholarships program, which annually awards a total of $25,000 each to one…

Treatment with ELX-02 in combination with Kalydeco (ivacaftor) was well-tolerated, but failed to meet efficacy goals in a clinical trial that tested the combo in people with cystic fibrosis (CF) caused by nonsense mutations. Eloxx Pharmaceuticals, the company developing ELX-02, says the lack of efficacy may…

People with cystic fibrosis (CF) who have abnormal glucose tolerance — higher-than-normal blood sugar levels after eating — are more likely to experience clinical exacerbations of worsening lung function, according to a new study. This was found to be true even for patients who don’t meet the criteria for…

People with cystic fibrosis (CF) treated with Kalydeco (ivacaftor) may have higher levels of the medication in their body than is needed for a therapeutic effect, according to a new study. “A key finding of our study revealed that some patients have higher than expected [Kalydeco] concentrations which…